LTZ Therapeutics is a clinical-stage immunotherapy biotech developing macrophage- and monocyte-activating cancer therapies through its proprietary Universal Myeloid Cell Engager (U-MCE) platform. Its lead program LTZ-301 is a CD79b-targeting bispecific antibody in Phase 1 trials for relapsed or refractory non-Hodgkin lymphoma, with a second program LTZ-232 advancing toward IND. Founded by former Genentech executives in 2022, LTZ operates from Redwood City, California and Shenzhen, China, and has signed strategic collaborations with GSK and Eli Lilly across oncology and autoimmune indications.
1
Round
4
Tags
May 6, 2026
Latest raise
Funding activity · 1 round
May 6, 2026
$38M
Series B
Led by GL Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
